Skip to main content

Lupus (Systemic Lupus Erythematosus) and cannabis in New York

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Up to 60-day supply as …
POSSESSION
$0/yr
STATE FEE
1–7 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

New York statute and program

The New York Medical Cannabis Program is the operating authority for New York patient certification. The authoritative legal text is: New York Cannabis Law (Article 4). The program portal is at New York Medical Cannabis Program.

What the evidence says about cannabis and Lupus (Systemic Lupus Erythematosus)

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system produces autoantibodies that attack the body's own tissues. Inflammation can affect joints, skin, kidneys, blood, lungs, heart, and the nervous system. Lupus is a relapsing-remitting disease — patients experience flares and periods of relative quiescence.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Lupus (Systemic Lupus Erythematosus) page.

How to qualify in New York

The New York Medical Cannabis Program requires the following registration steps for a Lupus (Systemic Lupus Erythematosus) patient (or any qualifying diagnosis):

  1. See a New York medical practitioner registered with the Office of Cannabis Management. A New York-licensed physician, nurse practitioner, dentist, podiatrist, midwife, or physician assistant registered with the Office of Cannabis Management (OCM) Medical Cannabis Program must determine that medical cannabis may benefit the patient. Since the 2022 reform, registered practitioners may certify patients for any condition for which the practitioner believes medical cannabis is appropriate — practitioner-discretion model.
  2. Receive your certification through the OCM patient portal. The practitioner issues an electronic certification through the OCM Medical Cannabis Program portal. The certification is the controlling document; patients no longer must complete a separate registration step since the 2022 streamlining — the certification itself constitutes registration in the program.
  3. Use the certification at any New York medical dispensary. Patients present the printed or electronic certification along with a New York driver license or state ID at any of the New York licensed medical dispensaries (Registered Organizations). The OCM separately issues a physical medical cannabis card on request, but the card is no longer mandatory for purchase since 2022.
  4. No state patient fee. New York eliminated the patient registration fee in 2022. Patients pay only the practitioner certification fee plus product costs. The certification is valid for the duration set by the practitioner (typically one year). Adult-use retail also operates statewide for adults 21+; medical patients retain higher possession limits (60-day supply), lower taxation, and statutory employment protections under New York Labor Law §201-D.
State registration fee
$0
Physician visit (typical)
$125–$300
Certification to card
1–7 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full New York registration steps, fees, and reciprocity rules, see the New York cannabis-laws page.

ICD-10 code

A certifying physician documenting Lupus (Systemic Lupus Erythematosus) for the New York medical cannabis program will typically record ICD-10 M32.9 or SNOMED-CT 55464009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does New York list Lupus (Systemic Lupus Erythematosus) as a qualifying condition for medical cannabis?

No. New York's qualifying-condition list does not currently include Lupus (Systemic Lupus Erythematosus), and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Lupus (Systemic Lupus Erythematosus) in New York have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. New York program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a New York medical marijuana card for Lupus (Systemic Lupus Erythematosus)?

Because New York does not currently list Lupus (Systemic Lupus Erythematosus) as a qualifying condition, a card for Lupus (Systemic Lupus Erythematosus) alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in New York who is registered with New York Medical Cannabis Program and willing to evaluate Lupus (Systemic Lupus Erythematosus) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. New York honors out-of-state medical cards under its reciprocity rules — uncommon, and worth verifying before relying on it. The state minimum patient age is 18; minors generally require a parent or legal guardian to act as caregiver. The authoritative source for the current process is the New York Medical Cannabis Program site at https://cannabis.ny.gov/medical-cannabis; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Lupus (Systemic Lupus Erythematosus)?

For Lupus (Systemic Lupus Erythematosus), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Lupus (Systemic Lupus Erythematosus) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Lupus (Systemic Lupus Erythematosus) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Lupus (Systemic Lupus Erythematosus) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Lupus (Systemic Lupus Erythematosus); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. New York Cannabis Law (Article 4)accessed May 15, 2026
  2. New York Office of Cannabis Managementaccessed May 15, 2026
  3. NORML: New York Lawsaccessed May 15, 2026
  4. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases: Lupusaccessed May 18, 2026
  5. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026

    “Substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults.”

  6. Lupus Foundation of America: Marijuana and Lupusaccessed May 18, 2026
  7. American College of Rheumatology: 2023 Guideline for SLE Management (executive summary)accessed May 18, 2026
  8. MedlinePlus: Systemic lupus erythematosusaccessed May 18, 2026